Supreme Court restores access to mail-order abortion pill mifepristone, for now

Justice Samuel Alito made headlines on Monday with his decision to issue an administrative stay of a lower court order that had restricted access to mifepristone, a commonly used abortion pill, across the nation. This move effectively restores expanded access to the drug, allowing it to be prescribed via telemedicine and obtained through mail or pharmacy services without the need for an in-person doctor’s visit, at least for the time being. The practice of telemedicine for prescribing mifepristone was approved by the Food and Drug Administration in 2023.

While Justice Alito did not provide an explanation for his decision, the temporary stay is set to expire on May 11. This suggests that the full court will need to make a decision on whether to grant an extended stay of the lower court ruling as ongoing litigation regarding the safety guidelines for mifepristone continues.

The legal battle over mifepristone’s accessibility stems from a case brought forth by the state of Louisiana, a state that has strict regulations on abortion. Louisiana sought to block mail-order access to the abortion pill, arguing that federal regulators had not adequately considered safety risks when eliminating the requirement for an in-person doctor visit. However, drug manufacturers, public health organizations, and abortion rights advocates maintain that the drug underwent rigorous safety reviews and has a lower adverse effects rate compared to commonly used medications like penicillin and Viagra.

The 5th U.S. Circuit Court of Appeals, which Justice Alito oversees, issued a nationwide order last Friday that prohibited the dispensing of mifepristone through telehealth providers or mail distribution while the legal proceedings are ongoing. This order took immediate effect, prompting the two primary makers of mifepristone, Danco Laboratories and GenBioPrio, to appeal to the Supreme Court to lift the lower court’s ruling.

In their filing to the Supreme Court, lawyers for Danco Laboratories emphasized the chaos and harm caused to patients, providers, pharmacies, and the drug-regulatory system as a result of the restrictions on mifepristone. They underscored the urgent need for emergency relief from the Supreme Court to address these issues.

This legal battle over mifepristone is not unprecedented. In 2024, the Supreme Court unanimously rejected a similar legal challenge to the drug, ruling that the doctors and anti-abortion groups who had filed the lawsuit did not have legal standing to challenge the drug’s regulations. As the debate over mifepristone’s accessibility and safety guidelines continues, the Supreme Court’s upcoming decision on the extended stay will have far-reaching implications for reproductive rights and healthcare access in the United States.